Consolidated Statements of Earnings (unaudited) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Revenue:
Product revenue	$ 24,465,000	$ 21,450,000	$ 72,821,000	$ 64,580,000
License revenue	87,000	2,854,000	262,000	3,279,000
Total revenue	24,552,000	24,304,000	73,083,000	67,859,000
Product costs and operating expenses:
Cost of goods sold	8,183,000	7,463,000	24,252,000	22,262,000
Research and development	2,936,000	2,808,000	8,964,000	7,541,000
Clinical and regulatory	1,022,000	1,104,000	3,326,000	3,327,000
Sales and marketing	6,188,000	5,831,000	19,279,000	18,318,000
General and administrative	1,714,000	881,000	5,013,000	3,660,000
Amortization of purchased technology and intangibles	359,000	212,000	1,032,000	621,000
Total product costs and operating expenses	20,402,000	18,299,000	61,866,000	55,729,000
Operating earnings	4,150,000	6,005,000	11,217,000	12,130,000
Other earnings (expenses):
Interest earnings	0	4,000	0	12,000
Interest expense	(3,000)	(3,000)	(10,000)	(10,000)
Foreign exchange gain (loss)	9,000	(9,000)	(11,000)	117,000
Earnings before income taxes	4,156,000	5,997,000	11,196,000	12,249,000
Income tax expense	(1,591,000)	(2,287,000)	(4,338,000)	(4,669,000)
Net earnings	$ 2,565,000	$ 3,710,000	$ 6,858,000	$ 7,580,000
Net earnings per share - basic (in dollars per share)	$ 0.16	$ 0.22	$ 0.43	$ 0.46
Net earnings per share - diluted (in dollars per share)	$ 0.16	$ 0.22	$ 0.42	$ 0.44